MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results
May 03, 2022 16:01 ET
|
MacroGenics, Inc.
Plan to start Phase 2/3 prostate cancer study with MGC018 by year-end Initiated Phase 1 study of MGC018 in combination with lorigerlimab in advanced solid tumorsTargeting mid-2022 start of Phase 1...
MacroGenics Provides Update on Corporate Progress and 2021 Financial Results
February 24, 2022 16:01 ET
|
MacroGenics, Inc.
Initiating Phase 1 dose escalation study of MGC018 in combination with lorigerlimab (formerly MGD019) in coming weeksPrioritizing MGD024 as lead CD3-based DART® molecule targeting CD123 and...
MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results
November 02, 2021 16:01 ET
|
MacroGenics, Inc.
Investigational New Drug (IND) application submitted for MGD024, a next generation DART® molecule targeting CD123 and CD3 for AMLU.S. Food & Drug Administration (FDA) approves MacroGenics’ GMP...
MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress
September 16, 2021 02:45 ET
|
MacroGenics, Inc.
Metastatic castration-resistant prostate cancer (mCRPC): 21 of 39 patients (54%) achieved ≥ 50% prostate-specific antigen (PSA) reduction; 10 of 16 (63%) RECIST-evaluable patients had anti-tumor...
MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress
September 12, 2021 19:00 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Sept. 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results
July 29, 2021 16:01 ET
|
MacroGenics, Inc.
Upcoming MGC018 and margetuximab MAHOGANY clinical data presentations at European Society for Medical Oncology (ESMO) MeetingConference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md.,...
MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting
May 19, 2021 17:05 ET
|
MacroGenics, Inc.
Dose escalation: anti-tumor activity observed in melanoma (including one confirmed partial response) and in mCRPC patientsCohort expansion in mCRPC: 11/22 (50%) patients have ≥ 50% PSA reduction;...
MacroGenics Announces Presentations at the 2021 AACR Annual Meeting
April 10, 2021 08:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, April 10, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Announces MGC018 Publication in Molecular Cancer Therapeutics
September 23, 2020 07:15 ET
|
MacroGenics, Inc.
Manuscript describes preclinical development of MGC018Phase 1 dose expansion trial evaluating MGC018 in patients with mCRPC, TNBC and NSCLC is currently recruiting patients ROCKVILLE, MD,...